Amgen (AMGN) stock had a bullish inflow of $149.2 million worth of trades on uptick and an outflow of $121.34 million in downticks on Wednesday. The total uptick to downtick ratio stood at 1.23. The net money flow into the stock was $27.86 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $31.95 million. An inflow of $19.64 million block trade was recorded on downticks. $51.59 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 2.63 in favor of the bulls. However, Amgen (AMGN) stock traded down $1.92 , and reached $169.71, a drop of -1.12% over the previous day. On a weekly basis, the stock is -2.91%, over the previous weeks close.
Amgen Inc. has lost 2.38% in the last five trading days and dropped 1.05% in the last 4 weeks. Amgen Inc. is up 13.72% in the last 3-month period. Year-to-Date the stock performance stands at 6.58%.
Amgen (AMGN) : Zacks Investment Research ranks Amgen (AMGN) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 10 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 15 research analysts is 2.37, which indicates as a Buy.
Amgen (NASDAQ:AMGN): stock was range-bound between the intraday low of $169.05 and the intraday high of $172.22 after having opened at $172.22 on Wednesdays session. The stock finally closed in the red at $172.22, a loss of -1.12%. The stock remained in the red for the whole trading day. The total traded volume was 3,300,683 shares. The stock failed to cross $172.22 in Wednesdays trading. The stocks closing price on Thursday was $171.63.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.